The Russian Direct Investment Fund (RDIF) and Virchow Biotech have signed an agreement to annually produce up to 200 million doses of Russia’s Covid-9 vaccine Sputnik V in India.

Based on a proven and well-studied platform of human adenoviral vectors, Sputnik V uses two different vectors for the two jabs in a course of inoculation.

The transfer of technology is anticipated to conclude in the second quarter of this year followed by a full-scale commercial production of the vaccine.

The Virchow Biotech capabilities will help the global supply of Sputnik V to RDIF’s international partners.

Russian Direct Investment Fund CEO Kirill Dmitriev said: “Vaccine partnerships are the only way to overcome the pandemic.

“The agreement with Virchow Biotech is an important step to facilitate the full-scale local production of the vaccine in India and to supply our international partners globally.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sputnik V is currently registered in 54 countries globally.

Last month, Mexican health regulator COFEPRIS authorised Sputnik V for emergency use after the country entered a contract to secure millions of vaccine doses.

On another note, Dyadic International (DYAI) is set to expand its partnership with South Korea’s Medytox to co-develop C1 manufactured Covid-19 vaccines and/or boosters.

If proven successful, these vaccines will be used against two or more of the existing and future Covid-19 variants.

Medytox Research and Development (R&D) senior executive vice-president and head Dr Gi-Hyeok Yang said: “Based on our experience and comparing the C1 technology platform against several other expression platforms such as CHO and insect cells, we believe that the fungi-derived C1 expression system is the most realistic technology to develop and manufacture multi-valent (i.e., tri-valent, and tetra-valent) vaccines rapidly and affordably against Covid-19 mutant viruses without the need for a large-scale bioreactor facility.”